Xiang Shi, Zhang Wenwen, Wang Zhichao, Chen Hui, Yang Chao
Oncology Research Center, Jiangxi University of Chinese Medicine, Nanchang, China.
Jiangxi Provincial Key Laboratory of Chinese Medicine Diagnosis and Rehabilitation of Malignant Tumors, Jiangxi University of Chinese Medicine, Nanchang, China.
Transl Cancer Res. 2025 May 30;14(5):2580-2593. doi: 10.21037/tcr-24-2155. Epub 2025 May 26.
is a chaperone protein that plays a role in several biological processes, including inflammation and cancer. is highly expressed in lung adenocarcinoma (LUAD). However, its exact function is still unclear. This study aimed to identify as a potential biomarker for predicting prognosis in LUAD.
We used bioinformatics methods to analyze the role of in LUAD and predict its downstream pathways. Our findings clarified the role of in cellular proliferation based on a series of experiments. Additionally, we investigated its effects on the cell cycle and apoptosis using flow cytometry.
We analyzed the expression levels of message RNA (mRNA) and protein in various normal human and tumor tissues using the The Cancer Genome Atlas (TCGA), Clinical Proteomic Tumor Analysis Consortium (CPTAC), and Human Protein Atlas (HPA) databases. Prognostic analysis of selected survival data from the TCGA database indicated that expression was associated with clinicopathological stages. The low expression group had significantly higher overall survival (OS) and disease-specific survival (DSS) rates than the high expression group. Additionally, the CancerSEA functional similarity analysis showed that was involved in several cellular functions. These included cell cycle stimulation, DNA damage response, invasion, and proliferation. Analysis of immune scores and immune cell infiltration using the ESTIMATE and TIMER databases revealed that high levels were associated with low infiltration of CD8 T cells and plasmacytoid dendritic cells (pDCs), while elevated infiltration of Th2 and T helper cells was also noted. Patients with high expression had lower scores in patient-derived xenografts, immune scores, and estimated scores. However, they exhibited notably higher T cell rejection rates. In vitro experiments further confirmed that knockdown significantly reduced the proliferation of H1299 cells.
These findings show that silencing expression or using inhibitors effectively improves treatment outcomes for LUAD. Targeting could be a powerful treatment strategy for LUAD.
[蛋白名称]是一种分子伴侣蛋白，在包括炎症和癌症在内的多种生物学过程中发挥作用。它在肺腺癌（LUAD）中高度表达。然而，其确切功能仍不清楚。本研究旨在确定[蛋白名称]作为预测LUAD预后的潜在生物标志物。
我们使用生物信息学方法分析[蛋白名称]在LUAD中的作用，并预测其下游通路。我们的研究结果基于一系列实验阐明了[蛋白名称]在细胞增殖中的作用。此外，我们使用流式细胞术研究了其对细胞周期和细胞凋亡的影响。
我们使用癌症基因组图谱（TCGA）、临床蛋白质组肿瘤分析联盟（CPTAC）和人类蛋白质图谱（HPA）数据库分析了[蛋白名称]信使核糖核酸（mRNA）和蛋白质在各种正常人类组织和肿瘤组织中的表达水平。对TCGA数据库中选定生存数据的预后分析表明，[蛋白名称]表达与临床病理分期相关。低[蛋白名称]表达组的总生存期（OS）和疾病特异性生存期（DSS）率显著高于高表达组。此外，CancerSEA功能相似性分析表明，[蛋白名称]参与了多种细胞功能。这些功能包括细胞周期刺激、DNA损伤反应、侵袭和增殖。使用ESTIMATE和TIMER数据库分析免疫评分和免疫细胞浸润表明，高水平的[蛋白名称]与CD8 T细胞和浆细胞样树突状细胞（pDC）的低浸润相关，同时也注意到Th2和辅助性T细胞的浸润增加。高[蛋白名称]表达的患者在患者来源的异种移植物、免疫评分和估计评分中得分较低。然而，他们表现出明显更高的T细胞排斥率。体外实验进一步证实，[蛋白名称]基因敲低显著降低了H1299细胞的增殖。
这些发现表明，沉默[蛋白名称]表达或使用[蛋白名称]抑制剂可有效改善LUAD的治疗效果。靶向[蛋白名称]可能是LUAD的一种有力治疗策略。
